AI Article Synopsis
Article Abstract
In order to evaluate the attractiveness of France for conducting international clinical trials, a survey is performed every two years among pharmaceutical companies that are based in France or have affiliates in France. Initiated in 2006, the current survey was much more representative than the previous ones with 20 companies accounting for 61% of the French market. This survey included 352 international phase II and III clinical studies carried out in 2004 and 2005, 74 countries, 17 345 centres and 137 989 patients. France has participated to half of the overall number of international clinical trials. France ranked among the best European recruiters (0,19 patient/1000 inhabitants) at the second position behind Scandinavian countries, taking in account numbers of inhabitants. Protocols are now to be given the go-ahead by Ethics Committee (CCPPRB) within 60 days. With a high productivity in phase IIb and in oncology, France is still an attractive place to locate clinical research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2515/therapie:2006070 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reactivation of latent HIV-1 by the glucocorticoid receptor modulator AZD9567.
J Virol
January 2025
Institute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany.
One key determinant of HIV-1 latency reversal is the activation of the viral long terminal repeat (LTR) by cellular transcription factors such as NF-κB and AP-1. Interestingly, the activity of these two transcription factors can be modulated by glucocorticoid receptors (GRs). Furthermore, the HIV-1 genome contains multiple binding sites for GRs.
View Article and Find Full Text PDFBI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors.
View Article and Find Full Text PDFPhages adapt to recognize an O-antigen polysaccharide site by mutating the 'backup' tail protein ORF59, enabling reinfection of phage-resistant .
Emerg Microbes Infect
January 2025
College of Veterinary Medicine, Institute of Comparative Medicine, Yangzhou University, Yangzhou, China.
Phages demonstrate remarkable promise as antimicrobial agents against antibiotic-resistant bacteria. However, the emergence of phage-resistant strains poses challenges to their effective application. In this paper, we presented the isolation of a phage adaptive mutant that demonstrated enhanced and sustained antibacterial efficacy through the co-evolution of () 111-2 and phage ZX1Δint .
View Article and Find Full Text PDFTraces of Earthquake: Traumatic Life Experiences and Their Effects on Volunteer Nurses in the Earthquake Zone-An Interpretative Phenomenological Study.
Public Health Nurs
January 2025
Department of Child and Adolescent Mental Health and Diseases, Faculty of Medicine, Altınbaş University, Istanbul, Turkey.
Introduction: It is crucial to understand the effects that traumatic events related to natural disasters have on individuals in as much detail as possible. However, the literature investigating the traumatic life experiences of nurses, who play a key role in disaster management, is still limited.
Objective: The aim of this study was to explore in depth the traumatic life experiences of volunteer nurses who participated in relief efforts after two major earthquakes in the southeastern region of Türkiye.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!